The Use of Plasma-Derived Concentrates

Pier Mannuccio Mannucci, Massimo Franchini

Research output: Chapter in Book/Report/Conference proceedingChapter


Von Willebrand disease (VWD) is the most common hereditary bleeding disorder that affects both males and females. It arises from quantitative or qualitative defects of von Willebrand factor (VWF) and causes mucous membrane and soft-tissue bleeding. The aim of treatment is to correct the dual defect of hemostasis caused by the abnormal/reduced VWF and the concomitant secondary deficiency of factor VIII (FVIII). Desmopressin (DDAVP) is the treatment of choice for patients with type 1 VWD who have FVIII and VWF levels of 10 IU/dL or more, while plasma-derived VWF concentrates, either containing FVIII or devoid of this moiety, are indicated for those who are unresponsive or insufficiently responsive to DDAVP (severe type 1, type 2, and type 3 VWD).

Original languageEnglish
Title of host publicationVon Willebrand Disease: Basic and Clinical Aspects
Number of pages7
ISBN (Print)9781405195126
Publication statusPublished - Mar 21 2011


  • Bleeding
  • Factor VIII
  • Therapy
  • Thrombosis
  • Von Willebrand disease
  • Von Willebrand factor
  • VWF/FVIII concentrates

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'The Use of Plasma-Derived Concentrates'. Together they form a unique fingerprint.

Cite this